Skip to content

Study · Not a test of the peptide alone · 1998

4 results

[The lymphocyte subpopulation in patients with duodenal ulcer and the immunocorrective activity of thymalin and dalargin].

Lukash NV, Polishchuk TF, Ludan VV

Likars'ka sprava1 May 1998

PMID9695565 (opens in a new tab)PepBankPUB-09695565
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymalin.

  1. 01HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome

    In duodenal ulcer, combined therapy including thymalin and dalargin increased T-lymphocytes to control levels.

    In plain wordsIn duodenal ulcer patients, combined therapy with thymalin and dalargin increased T-cell levels to those of controls.

    Peptide
    Thymalin
    Outcome
    IncreaseT-lymphocyte level
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Inclusion into the combined therapy of thymalin and dalargin was noted to be associated with a positive dynamics in the rise of T-lymphocytes, their subpopulations to the level in controls, percentage of TFS-RFC.
    2 context sentences
    Summary · context
    Kept under medical surveillance were 120 patients with duodenal ulcer running an uncomplicated course.
    Summary · context
    All patients and 30 healthy donors were studied for the status of the immunity T-system by spontaneous E-rosette formation (E-RFC) and availability of theophylline-resistant (TPP-RFC) and theophylline-sensitive (TPS-RFC) lymphocytes.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

  2. 02HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome

    In duodenal ulcer, combined therapy including thymalin and dalargin increased T-lymphocyte subpopulations to control levels.

    In plain wordsIn duodenal ulcer patients, combined therapy with thymalin and dalargin increased T-cell subgroup levels to those of controls.

    Peptide
    Thymalin
    Outcome
    IncreaseT-lymphocyte subpopulation levels
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Inclusion into the combined therapy of thymalin and dalargin was noted to be associated with a positive dynamics in the rise of T-lymphocytes, their subpopulations to the level in controls, percentage of TFS-RFC.
    2 context sentences
    Summary · context
    Kept under medical surveillance were 120 patients with duodenal ulcer running an uncomplicated course.
    Summary · context
    All patients and 30 healthy donors were studied for the status of the immunity T-system by spontaneous E-rosette formation (E-RFC) and availability of theophylline-resistant (TPP-RFC) and theophylline-sensitive (TPS-RFC) lymphocytes.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

  3. 03HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome

    In duodenal ulcer, combined therapy including thymalin and dalargin was associated with an increase in TFS-RFC percentage.

    In plain wordsIn duodenal ulcer patients, combined therapy with thymalin and dalargin was linked to a higher percentage of TFS-RFC cells.

    Peptide
    Thymalin
    Outcome
    IncreaseTFS-RFC percentage
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Inclusion into the combined therapy of thymalin and dalargin was noted to be associated with a positive dynamics in the rise of T-lymphocytes, their subpopulations to the level in controls, percentage of TFS-RFC.
    2 context sentences
    Summary · context
    Kept under medical surveillance were 120 patients with duodenal ulcer running an uncomplicated course.
    Summary · context
    All patients and 30 healthy donors were studied for the status of the immunity T-system by spontaneous E-rosette formation (E-RFC) and availability of theophylline-resistant (TPP-RFC) and theophylline-sensitive (TPS-RFC) lymphocytes.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

  4. 04HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome

    In duodenal ulcer, TFS-RFC indices did not differ from controls before or after combined therapy including thymalin and dalargin.

    In plain wordsIn duodenal ulcer patients, TFS-RFC measures did not differ from controls before or after combined therapy with thymalin and dalargin.

    Peptide
    Thymalin
    Outcome
    No significant changeTFS-RFC indices versus controls
    Study

    n: not reported in source

    Comparator
    healthy controls
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Indices for TFS-RFC did not differ from control ones either before or after the treatment.
    3 context sentences
    Summary · context
    Inclusion into the combined therapy of thymalin and dalargin was noted to be associated with a positive dynamics in the rise of T-lymphocytes, their subpopulations to the level in controls, percentage of TFS-RFC.
    Summary · context
    Kept under medical surveillance were 120 patients with duodenal ulcer running an uncomplicated course.
    Summary · context
    All patients and 30 healthy donors were studied for the status of the immunity T-system by spontaneous E-rosette formation (E-RFC) and availability of theophylline-resistant (TPP-RFC) and theophylline-sensitive (TPS-RFC) lymphocytes.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.